Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...